PATENT CLAIM ANALYSIS

Application Number: 15989860
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2019-03
Patent Classification: ["424", "133100"]

Abstract:
Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, lung, breast, mouse, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervix, ovary, and/or prostate cancer.

Claim (Index 26):
A method for detecting cancer in a subject, comprising:\n (a) applying one or more monoclonal antibodies that detect expression of a panel of markers consisting of GM3, GM2, GM1, GD1, GD1a, GD3, GD2, GT1b, A2B5, LeX, sLeX, LeY, SSEA-3, SSEA-4, sialyl SSEA-4, Globo H, Gb4, TF, Tn, sTn, CD44, CD24, CD45, CD90, CD133/1 and CD133/2 to a cell or tissue sample obtained from the subject; (b) assaying the binding of the one or more monoclonal antibodies to the cell or the tissue sample; and (c) comparing the binding with a normal control to determine the presence of the cancer in the subject.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 93.0
- Lexical Diversity: 1.61667
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14599174', '14798312', '15011544', '15011543', '15683685']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7575786074672302
- 35 USC 102 Novelty (BERT): 0.6618811300455492
- Combined Prediction Score: 0.7480088597250621
- Mean Citation Score: 719.916168
- Max Citation Score: 882.62274
- Similarity Product: 613.2413515640402

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test